Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q3 2020 Results - Earnings Call Transcript

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Recent Highlights Revenue of $74.6 million for the third quarter of 2020, an increase of 23% over the corresponding period of 2019 Precision oncology revenue of $60.4 million, an increas

Guardant Health Reports Third Quarter 2020 Financial Results

CrowdStrike

Datadog

Okta

Schrodinger 

Unity Software

Zscaler

Big Tech companies have been the hottest stocks on Wall Street all year, pre- and post-pandemic. But some experts think it's time for a new crop of dynamic up-and-comers in fields like virtual reality and health tech to take center stage in your portfolio.

Big Tech is under pressure. Here's where to find growth

The company is chasing a massive opportunity, but growth slowed this year.

Is Guardant Health Stock a Buy?

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available fo

Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the closings of an underwritten public offering of 7,700,000 shares of its common stock, which includes full exercise of the underwriter’s option to purchase 700,000 shares, at a public offering price of $102.00 per share, be

Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder

Intuitive Surgical

These companies are likely to be a lot bigger in 2040 -- and make patient investors a ton of money along the way.

3 Game-Changing Stocks to Buy and Hold for the Next 20 Years

Softbank is offering shares of the precision oncology company at a (temporary) bargain price.

Guardant Health Dips on Pricing of Equity Offering

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the pricing of an underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $102.00 per share, before deducting underwriting discounts and commissions, all of which are being sold by S

Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the commencement of a proposed underwritten public offering of 7,000,000 shares of its common stock being offered for sale by SoftBank Investment Advisers. In addition, SoftBank Investment Advisers expects to grant the underw

Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH). Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detect

Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy

Becton, Dickinson and Co.

Exact Sciences

Illumina

Natera

Invitae

QuidelOrtho Corp

COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.

7 Diagnostic and Genomic Stocks Storming Into October

Owens & Minor

SPDR S&P Health Care Services ETF

Bullish charts across the healthcare services subsector suggest that this niche segment could be the one to watch over the months ahead.

Healthcare Services Stocks Positioned for Move Higher

This company's diagnostic blood tests made it a hot IPO two years ago, but competitors are catching up, and COVID-19 could derail its critical study.

Has Guardant Health Lived Up to the Hype?

Innovative Industrial Properties

MongoDB

They're all innovative disruptors, but these three stocks could outperform Tesla over the next decade.

3 Great Stocks With Better Growth Prospects Than Tesla to Buy

Guardant Health: High Price But Lots Of Potential

Livongo Health Inc

Block

Sure, Tesla stock has been on fire this year. But these three stocks could be bigger winners over the long run.

3 Game-Changing Stocks That Are Better Buys Than Tesla

REDWOOD CITY, Calif., Sept.  01, 2020  (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference

Roku

Atlassian

Sometimes the best place to look for a stock that could double is checking out the ones that already have.

Got $3,000? Here Are 3 Stocks That Could Double Your Money -- and Sooner Than You Might Think

Edwards Lifesciences

Boston Scientific

Novocure

Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.

Intuitive Surgical, Edwards Lifesciences Lead Five Top Stocks To Watch As Coronavirus Cases Fall, Elective Procedures Rise

Fastly

Novavax

You don't need a huge initial investment with massive growth opportunities from these stocks.

Investing $3,000 in These 3 Stocks Could Make You a Fortune Over the Next Decade

Advanced Micro Devices

If you won't need that $1,200 to pay your immediate bills, why not use it to bolster your long-term financial plan?

Optimistic That You'll Get a Second Stimulus Check? Plan to Invest It in These 3 Stocks

Guardant Health on Monday announced that the U.S. Food and Drug Administration granted emergency use authorization for its Covid-19 test.

Guardant Health Coronavirus Test Gets Emergency OK; GH Stock Nears Buy Point

COVID-19 diagnostic expands testing supply, protects the continuity of essential cancer work at Guardant Health, and helps with reopening at Delaware State University COVID-19 diagnostic expands testing supply, protects the continuity of essential cancer work at Guardant Health, and helps with reopening at Delaware State University

Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test

REDWOOD CITY, Calif., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the following investor virtual conferences.

News for Guardant Health Inc Stock (GH)